Bausch Health Companies (BHC) Competitors

Grifols (NASDAQ:GRFS) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Do institutionals and insiders believe in GRFS or BHC?

78.7% of Bausch Health Companies shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer GRFS or BHC?

In the previous week, Grifols and Grifols both had 4 articles in the media. Bausch Health Companies' average media sentiment score of 1.56 beat Grifols' score of 1.07 indicating that Bausch Health Companies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Companies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, GRFS or BHC?

Grifols has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Do analysts prefer GRFS or BHC?

Bausch Health Companies has a consensus price target of $7.42, indicating a potential upside of 45.85%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Bausch Health Companies	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Does the MarketBeat Community prefer GRFS or BHC?

Bausch Health Companies received 8 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 60.91% of users gave Bausch Health Companies an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%
Bausch Health Companies	Outperform Votes 360 60.91%	Underperform Votes 231 39.09%

Is GRFS or BHC more profitable?

Grifols has a net margin of 0.00% compared to Bausch Health Companies' net margin of -0.48%. Grifols' return on equity of 0.00% beat Bausch Health Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	N/A	N/A	N/A
Bausch Health Companies	-0.48%	-577.82%	5.24%

Which has stronger earnings and valuation, GRFS or BHC?

Grifols has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.21B	0.86	$64.20M	$1.17	7.71
Bausch Health Companies	$9.73B	0.19	-$46M	-$0.11	-46.23

Summary

Grifols beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks.